THC valine hemisuccinate (THC-VHS, NB-1111, SBI-100) is a synthetic prodrug of tetrahydrocannabinol, developed at the University of Mississippi as a stabilised formulation for ophthalmic administration, for use in the treatment of glaucoma and other eye conditions requiring reduction in intraocular pressure.[1][2][3][4][5]
Identifiers | |
---|---|
| |
PubChem CID | |
Chemical and physical data | |
Formula | C30H39NO6 |
Molar mass | 509.643 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ Taskar PS, Patil A, Lakhani P, Ashour E, Gul W, ElSohly MA, et al. (September 2019). "Δ9-Tetrahydrocannabinol Derivative-Loaded Nanoformulation Lowers Intraocular Pressure in Normotensive Rabbits". Translational Vision Science & Technology. 8 (5): 15. doi:10.1167/tvst.8.5.15. PMC 6753841. PMID 31588378.
- ^ Sweeney C, Dudhipala N, Thakkar R, Mehraj T, Marathe S, Gul W, et al. (October 2021). "Effect of surfactant concentration and sterilization process on intraocular pressure-lowering activity of Δ9-tetrahydrocannabinol-valine-hemisuccinate (NB1111) nanoemulsions". Drug Delivery and Translational Research. 11 (5): 2096–2107. doi:10.1007/s13346-020-00871-9. PMID 33169348.
- ^ Sweeney C, Dudhipala N, Thakkar R, Mehraj T, Marathe S, Gul W, et al. (March 2022). "Impact of mucoadhesive agent inclusion on the intraocular pressure lowering profile of Δ9-tetrahydrocannabinol-valine-hemisuccinate loaded nanoemulsions in New Zealand white rabbits". International Journal of Pharmaceutics. 616: 121564. doi:10.1016/j.ijpharm.2022.121564. PMID 35151817.
- ^ US 8809261, Elsohly MA, Gul W, Repka MA, Majumdar S, "Compositions containing delta-9-THC-amino acid esters and process of preparation.", issued 19 August 2014, assigned to ElSohly Laboratories, Inc.
- ^ WO 2020/215164, Hsu E, Kumar U, Kumar R, "Compositions and methods for use of cannabinoids for neuroprotection", published 29 October 2020, assigned to Inmed Pharmaceuticals Inc.